Clinical update on teriparatide

Current Rheumatology Reports

Volumn 11, Issue 3, 2009, Pages 169-176

  Deal, Chad ^a   File, Elizabeth ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTROGEN; IBANDRONIC ACID; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; RECOMBINANT PROTEIN;

BONE STRENGTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG WITHDRAWAL; FRACTURE; FRACTURE HEALING; HUMAN; HYPERCALCEMIA; LEG CRAMP; MONOTHERAPY; NONHUMAN; OSTEOSARCOMA; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; BONE; COMPRESSIVE STRENGTH; DRUG EFFECT; FEMALE; MALE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; COMPRESSIVE STRENGTH; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; RECOMBINANT PROTEINS; RISK FACTORS; TERIPARATIDE;

EID: 70349573790     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0023-3     Document Type: Review

References (40)

1. R.M. Neer C.D. Arnaud J.R. Zanchetta, et al. 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441 11346808 10.1056/ NEJM200105103441904 1:CAS:528:DC%2BD3MXktVSgsbw%3D (Pubitemid 32402100)
2. S. Prevrhal J.H. Krege P. Chen, et al. 2009 Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment Curr Med Res Opin 25 921 928 19250060 10.1185/03007990902790993 1:CAS:528:DC%2BD1MXjsFylur8%3D
3. K.G. Saag E. Shane S. Boonen, et al. 2007 Teriparatide or alendronate in glucocorticoid-induced osteoporosis N Engl J Med 357 2028 2039 18003959 10.1056/NEJMoa071408 1:CAS:528:DC%2BD2sXhtlWis7rP (Pubitemid 350106710)
4. M.R. McClung J. San Martin P.D. Miller, et al. 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass Arch Intern Med 165 1762 1768 16087825 10.1001/archinte.165.15.1762 1:CAS:528:DC%2BD2MXpslGgs7c%3D (Pubitemid 41138965)
5. T.M. Keaveny D.W. Donley P.F. Hoffmann, et al. 2007 Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis J Bone Miner Res 22 149 157 17042738 10.1359/jbmr.061011 1:CAS:528:DC%2BD2sXhtVWnurk%3D (Pubitemid 46032608)
6. T.M. Keaveny P.F. Hoffmann B.H. Mitlak, et al. 2007 Comparison of the effects of teriparatide and alendronate on parameters of total hip strength as assessed by finite element analysis: results from the forteo and alendronate comparator trial J Bone Miner Res 22 Suppl1 S26
7. J.A. Kanis O. Johnell A. Oden, et al. 2008 FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 385 397 18292978 10.1007/s00198-007-0543-5 1:STN:280:DC%2BD1c7nvF2ntA%3D%3D
8. A.N. Tosteson L.J. Melton 3rd B. Dawson-Hughes, et al. 2008 Cost-effective osteoporosis treatment thresholds: the United States perspective Osteoporos Int 19 437 447 18292976 10.1007/s00198-007-0550-6 1:STN:280:DC%2BD1c7nvF2ntg%3D%3D
9. J.L. Vahle M. Sato G.G. Long, et al. 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety Toxicol Pathol 30 312 321 12051548 10.1080/01926230252929882 1:CAS:528:DC%2BD38Xks1Gntbg%3D (Pubitemid 34556102)
10. J.L. Vahle G.G. Long G. Sandusky, et al. 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose Toxicol Pathol 32 426 438 15204966 10.1080/01926230490462138 1:CAS:528:DC%2BD2cXlslSgtro%3D (Pubitemid 38998935)
11. A.H. Tashjian Jr B.A. Chabner 2002 Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women J Bone Miner Res 17 1151 1161 12096828 10.1359/jbmr.2002.17.7.1151 1:CAS:528:DC%2BD38XlsF2nurg%3D
12. K.D. Harper J.H. Krege R. Marcus B.H. Mitlak 2007 Osteosarcoma and teriparatide? J Bone Miner Res 22 334 17129179 10.1359/jbmr.061111 (Pubitemid 46167804)
13. R. Lindsay W.H. Scheele R. Neer, et al. 2004 Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis Arch Intern Med 164 2024 2030 15477438 10.1001/archinte.164.18.2024 (Pubitemid 39390560)
14. D.M. Black J.P. Bilezikian K.E. Ensrud, et al. 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N Engl J Med 353 555 565 16093464 10.1056/NEJMoa050336 1:CAS:528:DC%2BD2MXnsVWmtb0%3D (Pubitemid 41138937)
15. M.R. McClung 2006 Do current management strategies and guidelines adequately address fracture risk? Bone 38 2Suppl2 S13 S17 16403495 10.1016/j.bone.2005.11.012 (Pubitemid 43177167)
16. D.M. Black S.L. Greenspan K.E. Ensrud, et al. 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N Engl J Med 349 1207 1215 14500804 10.1056/NEJMoa031975 1:CAS:528:DC%2BD3sXns1Kmsrw%3D (Pubitemid 37152030)
17. J.A. Gasser P. Ingold A. Venturiere J.R. Green 2006 Chronic subcutaneous, but not single intravenous dosing of rats with bisphosponates resuts in reduced bone anabolic response to PTH J Bone Miner Res 21 Suppl1 S113
18. P.J. Kostenuik C. Capparelli S. Morony, et al. 2001 OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats Endocrinology 142 4295 4304 11564687 10.1210/en.142.10.4295 1:CAS:528:DC%2BD3MXnt1ert70%3D (Pubitemid 32907057)
19. S.R. Cummings M.R. McClung C. Christiansen, et al. 2008 A phase III study of the effects of denosumab on vertebral, nonvertebral, and hip fracture in women with osteoporosis: results from the FREEDOM Trial J Bone Miner Res 23 S80
20. R. Lindsay J. Nieves C. Formica, et al. 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis Lancet 350 550 555 9284777 10.1016/S0140-6736(97)02342-8 1:CAS:528:DyaK2sXlvVamsb0%3D (Pubitemid 27348431)
21. C. Deal M. Omizo E.N. Schwartz, et al. 2005 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial J Bone Miner Res 20 1905 1911 16234962 10.1359/JBMR.050714 1:CAS:528:DC%2BD2MXht1amt7nP (Pubitemid 41532775)
22. B. Ettinger J. San Martin G. Crans I. Pavo 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate J Bone Miner Res 19 745 751 15068497 10.1359/JBMR.040117 1:CAS:528:DC%2BD2cXktFGksrk%3D (Pubitemid 41094385)
23. R.G. Russell Z. Xia J.E. Dunford, et al. 2007 Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy Ann NY Acad Sci 1117 209 257 18056045 10.1196/annals.1402.089 1:CAS:528:DC%2BD1cXhtVGmurY%3D (Pubitemid 350191297)
24. P.D. Miller P.D. Delmas R. Lindsay, et al. 2008 Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate J Clin Endocrinol Metab 93 3785 3793 18682511 10.1210/jc.2008-0353 1:CAS:528:DC%2BD1cXht1Gmur%2FN
25. R. Eastell T. Nickelsen F. Marin, et al. 2009 Sequential treatment of severe postmenopausal osteoporosis following teriparatide: Final results of the randomized, controlled European study of Forsteo (EUROFORS) J Bone Miner Res 24 726 736 19049337 10.1359/jbmr.081215 1:CAS:528:DC%2BD1MXksF2ksL0%3D
26. F. Cosman J. Nieves M. Zion, et al. 2005 Daily and cyclic parathyroid hormone in women receiving alendronate N Engl J Med 353 566 575 16093465 10.1056/NEJMoa050157 1:CAS:528:DC%2BD2MXnsVaqsbY%3D (Pubitemid 41138938)
27. F. Cosman R.A. Wermers C. Recknor, et al. 2007 Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate J Bone Miner Res 22 Suppl1 S127
28. A.B. Hodsman L.J. Fraher P.H. Watson, et al. 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis J Clin Endocrinol Metab 82 620 628 9024265 10.1210/jc.82.2.620 1:CAS:528:DyaK2sXhtVWrsL0%3D (Pubitemid 27068640)
29. K.G. Saag J.R. Zanchetta J.P. Devogelaer, et al. 2008 Teriparatide versus alendronate for treatment of glucocorticoid-induced osteoporosis: 36-month results J Bone Miner Res 23 Suppl1 S49
30. M.F. Holick T.C. Chen 2008 Vitamin D deficiency: a worldwide problem with health consequences Am J Clin Nutr 87 1080S 1086S 18400738 1:CAS:528: DC%2BD1cXkvFehu7k%3D
31. E.A. File C.L. Deal 2007 BMD response to teriparatide in patients previously treated with bisphosphonate versus treatment naive patients Arthritis Rheum 56 S266
32. P. Chen J.H. Satterwhite A.A. Licata, et al. 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis J Bone Miner Res 20 962 970 15883636 10.1359/JBMR.050105 1:CAS:528:DC%2BD2MXlsFehtr0%3D (Pubitemid 40712820)
33. A. Jemal R. Siegal E. Ward, et al. 2006 Cancer statistics, 2006 CA Cancer J Clin 56 106 130 16514137 10.3322/canjclin.56.2.106
34. R.E. Coleman R.D. Rubens 1987 The clinical course of bone metastases from breast cancer Br J Cancer 55 61 66 3814476 1:STN:280:DyaL2s7ivVOmug%3D%3D
35. H. Oka T. Kondoh A. Seichi, et al. 2006 Incidence and prognostic factors of Japanese breast cancer patients with bone metastasis J Orthop Sci 11 13 19 16437343 10.1007/s00776-005-0966-9 (Pubitemid 43155851)
36. T.T. Andreassen C. Ejersted H. Oxlund 1999 Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures J Bone Miner Res 14 960 968 10352105 10.1359/jbmr.1999.14. 6.960 1:CAS:528:DyaK1MXjvFKqurw%3D (Pubitemid 29262891)
37. A. Nakajima N. Shimoji K. Shiomi, et al. 2002 Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34) J Bone Miner Res 17 2038 2047 12412812 10.1359/jbmr.2002.17.11.2038 1:CAS:528:DC%2BD38Xoslems7k%3D
38. M.P. Whyte S. Mumm C. Deal 2007 Adult hypophosphatasia treated with teriparatide J Clin Endocrinol Metab 92 1203 1208 17213282 10.1210/jc.2006-1902 1:CAS:528:DC%2BD2sXksVSrsL8%3D (Pubitemid 46556386)
39. J. Lundkvist O. Johnell C. Cooper D. Sykes 2006 Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women Osteoporos Int 17 201 211 16027955 10.1007/s00198-005-1959-4 1:STN:280:DC%2BD28%2FhtV2ktw%3D%3D (Pubitemid 43053582)
40. H. Liu K. Michaud S. Nayak, et al. 2006 The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis Arch Intern Med 166 1209 1217 16772249 10.1001/archinte.166.11.1209 1:CAS:528: DC%2BD28Xms1Ogu7w%3D (Pubitemid 43877630)